Implementing Steroid-Sparing Guidelines and Early-Onset Methotrexate Protocols for Pediatric Uveitis in the 2026 Uveitis Drug Sector
In early 2026, the management of pediatric uveitis, particularly in children with Juvenile Idiopathic Arthritis, is prioritizing "steroid-sparing" strategies to protect skeletal growth and hormonal development. These 2026 clinical protocols mandate the introduction of methotrexate or adalimumab within weeks of diagnosis if topical steroids do not achieve rapid and complete quietness. In early...
0 Comments 0 Shares 302 Views 0 Reviews